<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01687842</url>
  </required_header>
  <id_info>
    <org_study_id>P110911</org_study_id>
    <secondary_id>ID RCB 2012-A00488-35</secondary_id>
    <nct_id>NCT01687842</nct_id>
  </id_info>
  <brief_title>Social Cognition and Turner Syndrome</brief_title>
  <acronym>COGNITUR</acronym>
  <official_title>Social Cognition and Turner Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monocentric multidisciplinary study (psychologists, endocrinologists, psychiatrists, and&#xD;
      molecular biologists) to characterize social cognition in adolescents with Turner syndrome&#xD;
      (TS).&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  Turner syndrome with homogeneous 45,X karyotype.&#xD;
&#xD;
        -  Age between 8 and 18 years.&#xD;
&#xD;
        -  Somatic state compatible with the evaluation.&#xD;
&#xD;
        -  Functional language and IQ ≥ 80 for the transfer tests&#xD;
&#xD;
        -  Informed consent signed by the holders of parental authority, the patient and the mother&#xD;
           for her own participation (DNA collection).&#xD;
&#xD;
        -  Affiliation to Social Security (beneficiary or assignee).&#xD;
&#xD;
      The primary endpoint will be the overall score to the AQ (Autism Quotient) questionnaire and&#xD;
      to the SRS (Social Reciprocity Scale), in comparison to the expected scores for the general&#xD;
      population. For patients with scores above the threshold for SRS or QA validation of a&#xD;
      possible diagnosis of autism spectrum disorders will be performed with commonly used&#xD;
      diagnostic tools (ADIR (Lord et al, 1994), ADOS-G (Lord et al, 1999) and diagnostic criteria&#xD;
      of DSM IV-TR).&#xD;
&#xD;
      Secondary criteria will include the results of standardized tests to assess autistic features&#xD;
      (AQ, ADI-R, ADOS, DSM IV-TR criteria), intellectual efficiency (Wechsler scales), psychiatric&#xD;
      comorbidities (Kiddie-SADS) and sociocognitive profile (SpeX test, Social cognition,&#xD;
      Perception, eXecutive functions).&#xD;
&#xD;
      A DNA sample will be collected from the patient and her mother. The observation period is 2&#xD;
      days for the patient and about 1 hour for the mother. The total duration of the study is 3&#xD;
      years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be recruited to the study by their pediatric endocrinologist during routine&#xD;
      monitoring visits. They will then be contacted by phone or by mail for an appointment with&#xD;
      their mother for more oral and written information consisting of an information notice and&#xD;
      informed consent form. The recruitment of Turner syndrome patients will be based on the&#xD;
      Reference Centre for Rare Endocrine Growth Disorders (AP-HP, Robert Debré, Armand Trousseau&#xD;
      and Necker hospitals).&#xD;
&#xD;
      The parental origin of the remaining X chromosome will be analyzed using microsatellite&#xD;
      analysis and comparison of the profile of the patient and her mother.&#xD;
&#xD;
      Statistical analysis will be conducted under the supervision of Professor C. ALBERTI using&#xD;
      commonly accepted standards. All tests will be bilateral. Given the exploratory nature of the&#xD;
      study, a significance threshold of 10% will be used. Statistical analyzes will be performed&#xD;
      using SAS software V 9.2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall score to the AQ (Autism Quotient) questionnaire.</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SRS (Social Reciprocity Scale), in comparison to the expected scores for the general population.</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Socio-cognitive profile and parent of origin of the intact X chromosome</measure>
    <time_frame>2 days</time_frame>
    <description>Results of standardized tests to assess autistic features (AQ, ADI-R, ADOS, DSM IV-TR criteria), intellectual efficiency (Wechsler scales), psychiatric comorbidities (Kiddie-SADS) and sociocognitive profile (SpeX test, Social cognition, Perception, eXecutive functions).&#xD;
Parent of origin of the intact X chromosome and its relationship to the autistic features.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Turner Syndrome</condition>
  <arm_group>
    <arm_group_label>Turner syndrome patients</arm_group_label>
    <description>Evaluation of 45,X Turner syndrome patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of 45,X Turner syndrome patients</intervention_name>
    <description>Evaluation of 45,X Turner syndrome patients</description>
    <arm_group_label>Turner syndrome patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Buccal DNA samples will be collected in the patient and her mother&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Turner syndrome patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Turner syndrome with homogeneous 45,X karyotype.&#xD;
&#xD;
          -  Age between 8 and 18 years.&#xD;
&#xD;
          -  Somatic state compatible with the evaluation.&#xD;
&#xD;
          -  Functional language and IQ ≥ 80 for the transfer tests&#xD;
&#xD;
          -  Informed consent signed by the holders of parental authority, the patient and the&#xD;
             mother for her own participation (DNA collection).&#xD;
&#xD;
          -  Affiliation to Social Security (beneficiary or assignee).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Additional condition associated with an autism spectrum disorder&#xD;
&#xD;
          -  Turner syndrome not related to an homogeneous 45,X karyotype&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude Carel, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Delorme Richard, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert Debre Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>September 6, 2012</study_first_submitted>
  <study_first_submitted_qc>September 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2012</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Turner Syndrome</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

